Treatment of Elderly Patients with Aplastic Anemia

Read full text Summarise with VIRAT
Authors: André Tichelli, Alicia Rovó, Constantijn J.M. Halkes, Austin Gladston Kulasekararaj
Cited by: 0
References: 35

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Untreated patients aged ≥60 with aplastic anemia (AA) have a poor prognosis, with inferior treatment outcomes. Old age, per se, is not a contraindication to treating a patient. In contrast to younger patients, the treatment decision-making process is not only based on disease-related factors but also on functional ability, comorbidity, and social support, which need to be evaluated carefully. In case of eligibility to treat, immunosuppression is the first-line treatment option. Depending on the urgency to obtain a hematological response (i.e., severe neutropenia or active infections), treatment should start with either the combination of anti-thymocyte globulin (ATG), cyclosporine (CSA), and eltrombopag, or an ATG-free treatment with the combination of CSA with or without eltrombopag. There is no place for hematopoietic stem cell transplantation (HCT) as a first-line option, unless using syngeneic HCT. For refractory or relapsed patients after immunosuppressive treatment (IST), second-line treatment with other immunosuppressive drugs or HCT, provided they are eligible, should be considered. In this chapter, we aim to provide some guidance on how to approach the treatment of elderly patients with aplastic anemia.

Fields of Study & Subjects

Blood disorders and treatments Hematopoietic Stem Cell Transplantation Hematological disorders and diagnostics

Publication details

Journal / source
Springer eBooks
Pages
133–142
Publication date
25 March 2026
Language
EN
Document type
Book chapter